Intralesional methotrexate treatment for keratoacanthoma tumors: A retrospective study and review of the literature - 19/08/11
La Jolla, California; Iowa City, Iowa; and Tuscon, Arizona
Abstract |
Background |
Intralesional methotrexate (MTX) is an effective treatment for keratoacanthoma (KA).
Objective |
We sought to systematically examine response rates and adverse events in KA treated with intralesional MTX.
Methods |
All cases of KA treated with intralesional MTX at our institution from 1991 to 2006 were identified. A MEDLINE and PubMed search of cases of KA treated with intralesional MTX was also performed.
Results |
In all, 38 cases of KA treated with intralesional MTX were identified: 18 from our institution and 20 from the literature. Intralesional MTX achieved resolution in 92%, requiring an average of 2.1 injections an average of 18 days apart. Adverse events were rare, with two reports of pancytopenia in patients with chronic renal failure.
Limitations |
Use of single case reports, small series, and retrospective analysis are limitations.
Conclusion |
Intralesional MTX is a useful nonsurgical therapy for the treatment of KA. Histologic diagnosis before initiation of treatment is preferred. A complete blood cell count at baseline and during treatment should be considered to monitor for potential cytopenia.
Le texte complet de cet article est disponible en PDF.Plan
Funding sources: None. Conflicts of interest: None declared. |
Vol 56 - N° 6
P. 989-993 - juin 2007 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?